Becton, Dickinson and Company (BDX) Set to Announce Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) will be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $2.96 per share for the quarter. Becton, Dickinson and Company has set its FY24 guidance at $12.82-13.86 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company posted $2.98 EPS. On average, analysts expect Becton, Dickinson and Company to post $13 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $233.73 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The stock has a market capitalization of $67.52 billion, a P/E ratio of 55.39, a PEG ratio of 1.93 and a beta of 0.43. The company has a 50 day moving average price of $239.62 and a 200 day moving average price of $241.73. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BDX shares. Raymond James increased their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Barclays increased their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.